For example, midostaurin is added to target FLT3-ITD/TKD mutations; gemtuzumab ozogamicin (GO) is added to target the high expression of CD33; and CPX351 is added to target AML with myelodysplasia-related changes (AML-MRC). Here, CD33 is linked to acute myeloid leukemia.